# SK-1401 (rhGM-CSF Agent for Inhalation) GM-CSF Inhalation Pharmacokinetic Study

> **NCT02840708** · PHASE1 · COMPLETED · sponsor: **Niigata University Medical & Dental Hospital** · enrollment: 14 (actual)

## Conditions studied

- Pulmonary Alveolar Proteinosis, Autoimmune

## Interventions

- **DRUG:** Sargramostim

## Key facts

- **NCT ID:** NCT02840708
- **Lead sponsor:** Niigata University Medical & Dental Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2016-12
- **Final completion:** 2017-09-01
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2017-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02840708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02840708, "SK-1401 (rhGM-CSF Agent for Inhalation) GM-CSF Inhalation Pharmacokinetic Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02840708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*